SEARCH RESULT

Total Matching Records found : 171

New hepatitis cure far too costly -Martin Khor

-Asia News Network A controversy is brewing over a new cure for hepatitis C because it is extremely expensive and patients in middle-income countries like Malaysia will find it way beyond their budget. There are an estimated 400,000 Malaysians with hepatitis C, but this is probably a significant under-estimate since many people are not aware that they have the virus. Worldwide, 170 million people live with the hepatitis C virus (HCV), and every...

More »

SC agrees on urgent hearing of drug price plea

-The Telegraph The Supreme Court today agreed to take up "as early as possible" a plea challenging a recent NDA government decision that is alleged to have paved the way for a sharp rise in the prices of life-saving drugs. Petitioner Manohar Lal Sharma, a lawyer, has demanded a CBI probe into a September 22 government order that he says frees a list of medicines from pricing control. His public interest plea alleges...

More »

Has PM Modi bowed to US pressure on patent laws? -Rema Nagarajan

-The Times of India A paragraph buried in the US-India joint statement, which talks of establishing an annual high-level Intellectual Property (IP) working group as part of the Trade Policy Forum, has made health activists across the world apprehensive that the Modi government might be bending to US pressure to change its patent laws. Several health policy experts and activists have issued statements urging India not to give in to US...

More »

New drug era -Shamnad Basheer

-The Indian Express Prime Minister Narendra Modi's US visit is likely to throw up highly contentious intellectual property rights issues. Indeed, for the last several years, US drug majors and their European counterparts have lobbied hard to demonise the Indian patent regime. But the government must continue to defend the law and stand its ground. Particularly since our own industrial moguls have caved in and are less vocal about their opposition...

More »

Government curbs power of regulator to cap HIV, cancer drug prices -Rupali Mukherjee

-The Times of India MUMBAI: In a move that will disappoint many patients, the government has withdrawn certain powers of the drug pricing regulator that allowed it to cap prices of widely prescribed anti-diabetes, cancer, HIV, tuberculosis and cardiac medicines. The National Pharmaceutical Pricing Authority (NPPA) said it is withdrawing "with immediate effect" - a guideline that had allowed it to put price caps on crucial medicines - to comply with a...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close